Tvardi Therapeutics (TVRD) FY2025 10-K Risk Factors: 77 New, 68 Dropped

What the changes say

Tvardi Therapeutics completed a reverse merger, shifting its risk profile entirely toward clinical development of TTI-101 and TTI-109.

What changed since the prior 10-K

New

NewRisks Related to Our Financial Position and Need for Additional Capital
We have a limited operating history, which may make it difficult to evaluate our prospects and likelihood of success
We have a limited operating history since 2017 with no approved products and no revenue generated to date.
NewRisks Related to Our Financial Position and Need for Additional Capital
We have not generated any revenue to date and may never become or remain profitable
We have not generated any revenue and may never become profitable as our product candidates require extensive development.
NewRisks Related to Our Financial Position and Need for Additional Capital
Our financial condition raises substantial doubt as to our ability to continue as a going concern
Our financial condition raises substantial doubt about our ability to continue as a going concern.
NewRisks Related to Our Financial Position and Need for Additional Capital
We will require substantial additional capital to fund our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs, future commercialization efforts or other operations
We held $20.7 million in cash and $10.1 million in short-term investments as of December 31, 2025, and require substantial additional capital.
NewRisks Related to Our Financial Position and Need for Additional Capital
The amount of our future losses is uncertain, and our quarterly and annual operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline
Our operating results may fluctuate significantly and fall below investor expectations, causing our stock price to decline.
NewRisks Related to Research and Development and the Biopharmaceutical Industry
Preclinical and clinical development involves a lengthy, complex and expensive process, with an uncertain outcome
Preclinical and clinical development is lengthy, complex, expensive, and subject to a high rate of attrition.
NewRisks Related to Research and Development and the Biopharmaceutical Industry
Our ongoing and future clinical trials may reveal significant adverse events or unexpected drug-drug interactions not seen in preclinical studies and may result in a safety profile that could delay or prevent regulatory approval or market acceptance of any of our product candidates
Our clinical trials may reveal adverse events or unexpected drug-drug interactions not seen in preclinical studies.
NewRisks Related to Research and Development and the Biopharmaceutical Industry
We may be subject to additional risks because we intend to evaluate our product candidates in combination with the standard of care for the indications that we are pursuing
We intend to evaluate our product candidates in combination with the standard of care, introducing new efficacy and safety risks.
NewRisks Related to Research and Development and the Biopharmaceutical Industry
We may experience delays in initiating, completing or ultimately be unable to complete, the development and commercialization of TTI-101, TTI-109 or any other product candidates
We may experience delays in initiating or completing clinical trials for TTI-101, TTI-109, or other product candidates.
NewRisks Related to Research and Development and the Biopharmaceutical Industry
Interim, blinded and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available or as additional analyses are conducted and as the data are subject to audit and verification procedures that could result in material changes in the final data
Interim and preliminary data from our clinical trials, such as our Phase 2 IPF trial, may change as more patient data become available.
NewRisks Related to Research and Development and the Biopharmaceutical Industry
If we encounter difficulties enrolling patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected
Difficulties enrolling patients in our clinical trials could delay or adversely affect our clinical development activities.
NewRisks Related to Research and Development and the Biopharmaceutical Industry
The design or execution of our ongoing and future clinical trials may not support marketing approval
Flaws in the design or execution of our ongoing Phase 2 clinical trial of TTI-101 in HCC may prevent marketing approval.
NewRisks Related to Research and Development and the Biopharmaceutical Industry
We may not be successful in our efforts to identify or discover additional product candidates in the future
NewRisks Related to Research and Development and the Biopharmaceutical Industry
Due to our limited resources and access to capital, we must make decisions on the allocation of resources to certain programs and product candidates; these decisions may prove to be wrong and may adversely affect our business
NewRisks Related to Research and Development and the Biopharmaceutical Industry
We may in the future conduct clinical trials for current or future product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such clinical trials
NewRisks Related to Research and Development and the Biopharmaceutical Industry
Although we have received a Fast Track designation from the FDA for TTI-101 for HCC, we may not benefit from a faster development or regulatory review or approval process, and a Fast Track designation does not increase the likelihood that our product candidates will receive marketing approval
NewRisks Related to Research and Development and the Biopharmaceutical Industry
Even if a product candidate we develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success
NewRisks Related to Research and Development and the Biopharmaceutical Industry
We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than us
NewRisks Related to Research and Development and the Biopharmaceutical Industry
Compliance with governmental regulations regarding the treatment of animals used in research could increase our operating costs, which would adversely affect the commercialization of our products
NewRisks Related to Research and Development and the Biopharmaceutical Industry
If product liability lawsuits are brought against us, we may incur substantial financial or other liabilities and may be required to limit commercialization of our product candidates
NewRisks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance
Further, the FDA and its foreign counterparts may respond to any NDA that we may file by defining requirements that we do not anticipate. Such responses could delay clinical development of TTI-101, TTI-109 or any other current or future product candidates
NewRisks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance
Coverage and reimbursement may be limited or unavailable or pricing unfavorable in certain market segments for our product candidates, if approved, which could make it difficult for us to sell any product candidates profitably
NewRisks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance
In the United States, as well as foreign jurisdictions, no uniform policy of coverage and reimbursement for products exists among third-party payors
NewRisks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance
Recently enacted legislation, future legislation and other healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and commercialize product candidates and may affect the prices we may set
NewRisks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance
Congress is considering proposed legislation intended to further reduce healthcare costs with alternatives to replace the expired ACA subsidies
NewRisks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance
If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
NewRisks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance
Our future growth may depend, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties that could materially adversely affect our business
NewRisks Related to Our Intellectual Property
procedural, documentary, fee payment and other similar provisions during the patent application process. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business
NewRisks Related to Our Intellectual Property
The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we, our licensor or any future collaborators or partners will be successful in protecting our product candidates by obtaining and defending patents
NewRisks Related to Our Intellectual Property
We do not currently own or in-license any composition of matter patent protection for the TTI-101 molecule. As such, we rely solely upon patents related to methods of use, manufacturing and pharmaceutical compositions
NewRisks Related to Our Intellectual Property
It is difficult and costly to protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection
NewRisks Related to Our Intellectual Property
all relevant information has been identified. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our own patent portfolio
NewRisks Related to Our Intellectual Property
Our intellectual property licensed from third parties may be subject to retained rights
NewRisks Related to Our Intellectual Property
Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time
NewRisks Related to Our Intellectual Property
Changes in the interpretation of patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products
NewRisks Related to Our Intellectual Property
We may not be able to seek or obtain patent protection throughout the world or enforce such patent protection once obtained
NewRisks Related to Our Intellectual Property
In order to protect our competitive position around our product candidates, we may become involved in lawsuits to enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful and which may result in our own or in-licensed patents being found invalid or unenforceable
NewRisks Related to Our Intellectual Property
If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates
NewRisks Related to Our Intellectual Property
Others may challenge inventorship or claim an ownership interest in our intellectual property which could expose us to litigation and have a significant adverse effect on our prospects
NewRisks Related to Our Intellectual Property
We may be subject to claims by third parties asserting that our employees or we have misappropriated our intellectual property or claiming ownership of what we regard as our own intellectual property
NewRisks Related to Our Intellectual Property
If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
NewRisks Related to Our Intellectual Property
collaborators. A competitor’s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business
NewRisks Related to Our Intellectual Property
A third party may hold intellectual property, including patent rights that are important or necessary to the development of our product candidates. It may be necessary for us to use the patented or proprietary technology of one or more third parties to commercialize our current and future product candidates
NewRisks Related to Our Intellectual Property
If disputes over intellectual property that we have licensed or in the future have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates
NewRisks Related to Our Intellectual Property
If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our trademarks of interest and our business may be adversely affected
NewRisks Related to Our Intellectual Property
Intellectual property rights do not necessarily address all potential threats to our business
NewRisks Related to Our Reliance on Third Parties
If any of our relationships with these third-party CROs or others terminate, we may not be able to enter into arrangements with alternative CROs or other third parties or to do so on commercially reasonable terms
NewRisks Related to Our Reliance on Third Parties
Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay
NewRisks Related to Our Reliance on Third Parties
Because we rely on third-party manufacturing and supply vendors, including single-source vendors and vendors in foreign jurisdictions, our supply of research and development, preclinical and clinical development materials may become limited or interrupted or may not be of satisfactory quantity or quality
NewRisks Related to Our Reliance on Third Parties
If we are unable to enter into new collaborations, or if these collaborations are not successful, our business could be adversely affected
NewRisks Related to Our Reliance on Third Parties
The operations of our suppliers, some of which are located outside of the United States, are subject to additional risks that are beyond our control and that could harm our business, financial condition, results of operations and prospects
NewRisks Related to Our Reliance on Third Parties
Our suppliers and any future collaborators may need assurances that our financial resources and stability on a stand-alone basis are sufficient to satisfy their requirements for doing or continuing to do business with us
NewRisks Related to Managing Our Business and Operations
We may encounter difficulties in managing our growth, which could adversely affect our operations
NewRisks Related to Managing Our Business and Operations
If we lose key management personnel, or if we fail to recruit additional highly skilled personnel, our ability to develop current product candidates or identify and develop new product candidates will be impaired, could result in loss of markets or market share and could make us less competitive
NewRisks Related to Managing Our Business and Operations
We or the third parties upon whom we depend may be adversely affected by natural disasters, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster
NewRisks Related to Managing Our Business and Operations
The market price of our common stock is expected to be volatile
NewRisks Related to Managing Our Business and Operations
Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common stock
NewRisks Related to Managing Our Business and Operations
We have, and expect to continue to, incur significant legal, accounting and other expenses that we did not incur as a private company, including costs associated with public company reporting requirements
NewRisks Related to Managing Our Business and Operations
Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management
NewRisks Related to Managing Our Business and Operations
that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware
NewRisks Related to Managing Our Business and Operations
We do not anticipate paying any cash dividends in the foreseeable future
NewRisks Related to Managing Our Business and Operations
An active trading market for our common stock may not develop and our stockholders may not be able to resell their shares of common stock for a profit, if at all
NewRisks Related to Managing Our Business and Operations
Future sales of shares by existing stockholders could cause our stock price to decline
NewRisks Related to Managing Our Business and Operations
If we fail to attract and retain management and other key personnel, we may be unable to continue to successfully develop or commercialize our product candidates or otherwise implement our business plan
NewRisks Related to Managing Our Business and Operations
We are expected to take advantage of reduced disclosure and governance requirements applicable to smaller reporting companies, which could result in our common stock being less attractive to investors
NewRisks Related to Managing Our Business and Operations
Changes in tax laws may materially adversely affect our business, prospects, financial condition and operating results
NewRisks Related to Managing Our Business and Operations
We are subject to the SEC requirements applicable to reporting shell company business combinations. As a result, we are subject to more stringent reporting requirements, offering limitations and resale restrictions
NewRisks Related to Managing Our Business and Operations
In the past, securities class action or stockholder derivative litigation often follows certain significant business transactions, such as the sale of a business division or announcement of a merger. We are involved and may continue to be involved in this type of litigation in connection with the Merger
NewRisks Related to Managing Our Business and Operations
These material weaknesses could result in a misstatement of substantially all of our accounts or disclosures that would result in a material misstatement of our future annual or interim financial statements that would not be prevented or detected. These material weaknesses must be remediated by us
NewRisks Related to Managing Our Business and Operations
Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
NewRisks Related to Managing Our Business and Operations
Our issuance of additional capital stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders
NewRisks Related to Managing Our Business and Operations
If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
NewRisks Related to Managing Our Business and Operations
We will incur significant increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives
NewRisks Related to Managing Our Business and Operations
and resources to comply or defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations
NewRisks Related to Managing Our Business and Operations
attempts in the past and expect such attempts will continue in the future. A security incident or other interruption could disrupt our ability (and that of third parties with whom we work) to operate our business
NewRisks Related to Managing Our Business and Operations
Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations
NewRisks Related to Managing Our Business and Operations
The increasing use of social media platforms presents new risks and challenges

Dropped

DroppedRisks Related to the Merger with Tvardi
The Merger may not be completed on the terms or timeline currently contemplated, or at all
Merger completion conditions and risks related to the transaction between Cara and Tvardi.
DroppedRisks Related to the Merger with Tvardi
by Cara’s stockholders of the required stockholder proposals set forth in the proxy statement/prospectus included in the Registration Statement, (3) the requisite approval by Tvardi’s stockholders, and (4) other customary closing conditions and there can be no assurance that the Merger will be consummated
Exchange ratio stability and potential impact on Cara common stock price.
DroppedRisks Related to the Merger with Tvardi
The exchange ratio will not be adjusted based on the market price of Cara common stock, so the consideration at the closing of the Merger may have a greater or lesser value than at the time the Merger Agreement was signed
Cara net cash threshold requirements prior to closing the merger.
DroppedRisks Related to the Merger with Tvardi
Cara’s net cash may be less than $22.875 million at the closing of the Merger, which would result in Cara’s stockholders owning a smaller percentage of the combined company and, if Cara’s net cash is less than $18.0 million as of June 30, 2025, could even result in the termination of the Merger Agreement
Termination fees and expense reimbursements if the merger fails to complete.
DroppedRisks Related to the Merger with Tvardi
Failure to complete the Merger may result in Cara or Tvardi paying a termination fee to the other party and could harm the common stock price of Cara
Uncertainty of satisfying all closing conditions for the merger.
DroppedRisks Related to the Merger with Tvardi
If the conditions to the closing of the Merger are not met, the Merger may not occur
Material adverse changes occurring between the merger agreement date and closing.
DroppedRisks Related to the Merger with Tvardi
The Merger may be completed even though material adverse changes may result from the announcement of the Merger, industry-wide changes and/or other causes
Conflicting interests of Cara executive officers and directors in the merger.
DroppedRisks Related to the Merger with Tvardi
Some executive officers and directors of Cara have interests in the Merger that are different from the respective stockholders of Cara and that may influence them to support or approve the Merger without regard to the interests of the stockholders of Cara
Potential decline in Cara common stock price following the merger.
DroppedRisks Related to the Merger with Tvardi
The market price of Cara common stock following the Merger may decline as a result of the Merger
Reduced ownership and voting interest of pre-merger equity holders in the combined company.
DroppedRisks Related to the Merger with Tvardi
Cara and Tvardi equity holders will have a materially reduced ownership and voting interest in, and will exercise less influence over the management of, the combined company following the closing of the Merger as compared to their current ownership and voting interest in the respective companies
Restrictions on entering into alternative business combinations during the pendency of the merger.
DroppedRisks Related to the Merger with Tvardi
During the pendency of the Merger Agreement, Cara and Tvardi may not be able to enter into a business combination with another party at a favorable price because of restrictions in the Merger Agreement, which could adversely affect their respective businesses
Provisions discouraging third parties from submitting competing acquisition proposals.
DroppedRisks Related to the Merger with Tvardi
Certain provisions of the Merger Agreement may discourage third parties from submitting competing proposals, including proposals that may be superior to the arrangements contemplated by the Merger Agreement
DroppedRisks Related to the Merger with Tvardi
The Piper Sandler Opinion delivered by Piper Sandler to the Cara Board prior to the entry into the Merger Agreement does not reflect changes in circumstances that may occur after the date thereof
DroppedRisks Related to the Merger with Tvardi
The combined company may become involved in securities litigation that could divert management’s attention and harm the combined company’s business and insurance coverage may not be sufficient to cover all costs and damages
DroppedRisks Related to the Merger with Tvardi
Cara or Tvardi may waive one or more of the conditions to the Merger without recirculation of the proxy statement/prospectus or resoliciting stockholder approval
DroppedRisks Related to the Merger with Tvardi
Transfers of the combined company’s securities utilizing Rule 144 of the Securities Act may be limited
DroppedRisks Related to the Merger with Tvardi
Nasdaq may delist the combined company’s securities from trading on its exchange, which could limit investors’ ability to make transactions in its securities and subject the combined company to additional trading restrictions
DroppedRisks Related to the Merger with Tvardi
The financial projections considered by the Cara Board in evaluating the Merger and used by Piper Sandler at the direction of Cara in rendering its Opinion and performing its related financial analyses, reflect numerous variables, estimates and assumptions and are inherently uncertain
DroppedRisks Related to Cara’s Strategic Alternative Process and Potential Strategic Transaction
Failure to complete, or delays in completing, the Merger with Tvardi could materially and adversely affect Cara’s results of operations, business, financial results and/or stock price
DroppedRisks Related to Cara’s Strategic Alternative Process and Potential Strategic Transaction
Cara cannot be sure if or when the Merger will be completed
DroppedRisks Related to Cara’s Strategic Alternative Process and Potential Strategic Transaction
company. A liquidation would be a lengthy and uncertain process with no assurance of any value ever being returned to Cara stockholders
DroppedRisks Related to Cara’s Strategic Alternative Process and Potential Strategic Transaction
Lawsuits may be filed against Cara and the members of the Cara Board arising out of the Merger, which may delay or prevent the proposed merger
DroppedRisks Related to Cara’s Strategic Alternative Process and Potential Strategic Transaction
Cara is substantially dependent on its remaining employees to facilitate the consummation of the Merger
DroppedRisks Related to Cara’s Strategic Alternative Process and Potential Strategic Transaction
Cara may not be successful in completing the Merger, and any strategic transactions that it may consummate in the future could have negative consequences
DroppedRisks Related to Cara’s Strategic Alternative Process and Potential Strategic Transaction
anticipated results could significantly impair Cara’s ability to enter into any future strategic transactions and may significantly diminish or delay any future distributions to its stockholders
DroppedRisks Related to Cara’s Strategic Alternative Process and Potential Strategic Transaction
If Cara is successful in completing the Merger, it may be exposed to other operational and financial risks
DroppedRisks Related to Cara’s Strategic Alternative Process and Potential Strategic Transaction
Cara’s corporate restructuring and the associated reduction in workforce may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt its business
DroppedRisks Related to Cara’s Strategic Alternative Process and Potential Strategic Transaction
The impact and results of Cara’s ongoing strategic process are uncertain and may not be successful
DroppedRisks Related to Cara’s Financial Condition and Capital Requirements
Should Cara resume development activities in the future, Cara expects that research and development costs would increase significantly and Cara would continue to incur significant expenses and operating and net losses, as Cara develops and seeks regulatory approval for such product candidates
DroppedRisks Related to Cara’s Financial Condition and Capital Requirements
If Cara decides to resume development of Cara’s product candidate or any future product candidate, Cara will need additional funding and may be unable to raise capital when needed, which would force Cara to delay, reduce or eliminate its product development programs
DroppedRisks Related to Cara’s Financial Condition and Capital Requirements
Risks Related to Cara’s Business and the Development and Commercialization of Its Product and Potential Product Candidates
DroppedRisks Related to Cara’s Financial Condition and Capital Requirements
future product candidate, which would materially harm Cara’s business and Cara may not be able to generate sufficient revenues and cash flows to continue its operations
DroppedRisks Related to Cara’s Financial Condition and Capital Requirements
Should Cara resume development of its product candidate or any future product candidate, if Cara experiences delays or difficulties in the enrollment of patients in clinical trials, Cara’s receipt of necessary regulatory approvals could be delayed or prevented
DroppedRisks Related to Cara’s Financial Condition and Capital Requirements
arrangements that would delay its product development activities, should Cara resume development of its product candidate or any future product candidate, and adversely affect its business
DroppedRisks Related to Cara’s Financial Condition and Capital Requirements
as pandemics or other similar outbreaks, which could negatively impact Cara’s clinical development and commercialization timelines
DroppedRisks Related to Cara’s Financial Condition and Capital Requirements
Cara faces significant competition from other pharmaceutical and biotechnology companies, academic institutions, government agencies and other research organizations. Cara’s operating results will suffer if it fails to compete effectively
DroppedRisks Related to Cara’s Financial Condition and Capital Requirements
Among the companies that currently market or are developing therapies in the pruritus space that, if approved, Cara’s oral difelikefalin would potentially compete with include: Pfizer, AbbVie, Eli Lilly, Amgen, Regeneron, Leo Pharma, Galderma, Chugai, Incyte and others
DroppedRisks Related to Cara’s Financial Condition and Capital Requirements
Cara faces potential product liability exposure, and if successful claims are brought against Cara, Cara may incur substantial liability and, should Cara resume development of Cara’s product candidate or any future product candidate, may have to limit commercialization of a product candidate
DroppedRisks Related to Cara’s Financial Condition and Capital Requirements
Cara may expend its limited resources to pursue a particular product candidate or indication and fail to capitalize on its product candidate or indications that may be more profitable or for which there is a greater likelihood of success
DroppedRisks Related to Cara’s Financial Condition and Capital Requirements
Cara’s future growth may depend on its ability to identify and develop products and, should Cara resume development activities in the future, if Cara does not successfully identify and develop product candidates or integrate them into its operations, Cara may have limited growth opportunities
DroppedRisks Related to Cara’s Financial Condition and Capital Requirements
approval of a product candidate. Any marketing approval Cara ultimately obtains may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable
DroppedRisks Related to Cara’s Financial Condition and Capital Requirements
Should Cara resume development of its product candidate or any future product candidate, failure to obtain marketing approval in international jurisdictions would prevent a product candidate from being marketed abroad
DroppedRisks Related to Cara’s Financial Condition and Capital Requirements
Cara’s agreements with HCR contain various covenants and other provisions, which, if violated, could materially adversely affect Cara’s financial condition
DroppedRisks Related to Cara’s Financial Condition and Capital Requirements
consummation of the Asset Disposition, and (iii) Sellers to use their commercially reasonable efforts to obtain any needed consents and provide any needed notices in connection with the Asset Disposition
DroppedRisks Related to Cara’s Dependence on Third Parties
Any collaboration arrangements that Cara is a party to or may enter into in the future may not be successful, which, should Cara resume development activities, could adversely affect Cara’s ability to develop and ultimately commercialize its product candidate or any potential future product candidate
DroppedRisks Related to Cara’s Dependence on Third Parties
product candidate licensed to it by Cara. If one of Cara’s collaborators terminates its agreement with Cara, Cara may find it more difficult to attract new collaborators and Cara’s reputation in the business and financial communities could be adversely affected
DroppedRisks Related to Legal and Compliance Matters
If Cara fails to comply with federal and state healthcare laws, including fraud and abuse, and transparency laws, Cara could face substantial penalties and its business, results of operations, financial condition and prospects could be adversely affected
DroppedRisks Related to Legal and Compliance Matters
Additionally, certain states have adopted their own privacy and security laws and regulations for health information, some of which may be more stringent than HIPAA
DroppedRisks Related to Legal and Compliance Matters
In addition to data privacy and security laws, Cara is or may become contractually subject to industry standards adopted by industry groups. Cara is also bound by other contractual obligations related to data privacy and security, and Cara’s efforts to comply with such obligations may not be successful
DroppedRisks Related to Legal and Compliance Matters
In March 2010, the Health Care Reform Law was signed into law, which includes provisions that have changed, and likely will continue to change, health care financing and the delivery of health care in the United States
DroppedRisks Related to Legal and Compliance Matters
Cara’s business involves the use of hazardous materials and Cara and its third-party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how Cara does business
DroppedRisks Related to Intellectual Property
It is difficult and costly to protect Cara’s proprietary rights and as a result Cara may not be able to ensure their protection and all patents will eventually expire
DroppedRisks Related to Intellectual Property
If Cara or any current or future collaboration partner are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in any litigation would harm Cara’s business
DroppedRisks Related to Intellectual Property
be existing patents of which Cara is not aware that its current or potential future product candidates may inadvertently infringe
DroppedRisks Related to Intellectual Property
Cara may be involved in lawsuits to protect or enforce its patents or the patents of its licensors, which could be expensive, time consuming and may ultimately be unsuccessful
DroppedRisks Related to Intellectual Property
Cara may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms
DroppedRisks Related to Intellectual Property
Cara may be subject to claims that its employees have wrongfully used or disclosed alleged trade secrets of their former employers
DroppedRisks Related to Intellectual Property
Cara may not be able to protect its intellectual property rights throughout the world
DroppedRisks Related to Intellectual Property
The validity and enforceability of the patents and applications that cover difelikefalin can be challenged by competitors
DroppedRisks Related to Employee Matters and Managing Growth
Cara depends on skilled personnel to operate its business effectively in a rapidly changing market, and if Cara is unable to retain existing or hire additional personnel when needed, Cara’s ability to develop and sell its products could be harmed
DroppedRisks Related to Employee Matters and Managing Growth
filer at the end of 2024, which would allow it to forgo the auditor attestation requirement. While Cara has previously voluntarily complied with the auditor attestation requirement when it qualified as a non-accelerated filer in 2023, it has forgone the auditor attestation for the fiscal year ended December 31, 2024
DroppedRisks Related to Ownership of Cara Common Stock
If Cara fails to regain and maintain compliance with the continued listing standards of the Nasdaq Capital Market, Cara may be delisted and the price of its common stock, its ability to access the capital markets and its financial condition could be negatively impacted
DroppedRisks Related to Ownership of Cara Common Stock
On January 16, 2025, Cara received a letter from the Staff notifying the company that Cara had regained compliance with the minimum bid price requirement. The closing bid price of the Company’s common stock was at or above $1.00 per share for ten consecutive business days, and Nasdaq considers the matter closed
DroppedRisks Related to Ownership of Cara Common Stock
The market price of Cara’s common stock has been, and is likely to continue to be, highly volatile, and you may not be able to resell your shares at or above the price you paid for them
DroppedRisks Related to Ownership of Cara Common Stock
Cara’s quarterly operating results may fluctuate significantly
DroppedRisks Related to Ownership of Cara Common Stock
Changes to existing tax laws, or challenges to Cara’s tax positions could adversely affect its business and financial condition
DroppedRisks Related to Ownership of Cara Common Stock
Because Cara does not intend to pay dividends on its common stock, your returns will be limited to any increase in the value of Cara’s stock
DroppedRisks Related to Ownership of Cara Common Stock
Provisions in Cara’s corporate charter documents and under Delaware law may prevent or frustrate attempts by Cara’s stockholders to change its management and hinder efforts to acquire a controlling interest in Cara, and the market price of Cara’s common stock may be lower as a result

Reworded

100% rewrittenRisks Related to Managing Our Business and Operations
Our ability to use net operating loss carryforwards and other tax attributes may be limited, including as a result of the Merger
Updated U.S. federal and state NOL carryforward figures to $383.6 million and $419.2 million as of December 31, 2025.
Was: The use of Cara’s net operating loss carryforwards and research tax credits may be limited
99% rewrittenRisks Related to Our Financial Position and Need for Additional Capital
We have incurred significant net losses since inception, and we expect to continue to incur significant net losses for the foreseeable future
Replaced legacy Cara product history with Tvardi's early-stage profile, reporting net losses of $18.2 million and $29.4 million for 2025 and 2024.
Was: Cara has incurred significant losses from Cara’s inception, and Cara anticipates that it may incur losses in the foreseeable future
96% rewrittenRisks Related to Managing Our Business and Operations
If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired
Removed legacy filer status details and updated internal control disclosures to reflect status as a newly public entity.
Was: If Cara fails to maintain proper and effective internal controls, Cara’s ability to produce accurate financial statements on a timely basis could be impaired
94% rewrittenRisks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance
Governments outside the United States tend to impose strict price controls, which may adversely affect our revenue, if any
Removed references to resuming discontinued development activities and updated international pricing and reimbursement controls for EU markets.
Was: Governments outside the United States tend to impose strict price controls, which may adversely affect Cara’s revenues, if any
90% rewrittenRisks Related to Managing Our Business and Operations
Our employees, independent contractors, consultants, commercial partners, collaborators and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
Expanded employee misconduct scope to explicitly include independent contractors, commercial partners, collaborators, and vendors.
Was: Cara’s employees, independent contractors, consultants, and commercial partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on Cara’s business
81% rewrittenRisks Related to Managing Our Business and Operations
If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline
Updated equity research analyst coverage risks to reflect current trading market dynamics for common stock.
Was: If equity research analysts cease to publish research or reports about Cara or if they publish unfavorable research or reports about the company, its business or its market, Cara’s stock price and trading volume could decline

All 83 risk factors

Headings as the filing states them, in filing order.

Risks Related to Our Financial Position and Need for Additional Capital

01We have incurred significant net losses since inception, and we expect to continue to incur significant net losses for the foreseeable future99% rewritten
02We have a limited operating history, which may make it difficult to evaluate our prospects and likelihood of successNew
03We have not generated any revenue to date and may never become or remain profitableNew
04Our financial condition raises substantial doubt as to our ability to continue as a going concernNew
05We will require substantial additional capital to fund our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs, future commercialization efforts or other operationsNew
06The amount of our future losses is uncertain, and our quarterly and annual operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or declineNew

Risks Related to Research and Development and the Biopharmaceutical Industry

07Preclinical and clinical development involves a lengthy, complex and expensive process, with an uncertain outcomeNew
08Our ongoing and future clinical trials may reveal significant adverse events or unexpected drug-drug interactions not seen in preclinical studies and may result in a safety profile that could delay or prevent regulatory approval or market acceptance of any of our product candidatesNew
09We may be subject to additional risks because we intend to evaluate our product candidates in combination with the standard of care for the indications that we are pursuingNew
10We may experience delays in initiating, completing or ultimately be unable to complete, the development and commercialization of TTI-101, TTI-109 or any other product candidatesNew
11Interim, blinded and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available or as additional analyses are conducted and as the data are subject to audit and verification procedures that could result in material changes in the final dataNew
12If we encounter difficulties enrolling patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affectedNew
13The design or execution of our ongoing and future clinical trials may not support marketing approvalNew
14We may not be successful in our efforts to identify or discover additional product candidates in the futureNew
15Due to our limited resources and access to capital, we must make decisions on the allocation of resources to certain programs and product candidates; these decisions may prove to be wrong and may adversely affect our businessNew
16We may in the future conduct clinical trials for current or future product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such clinical trialsNew
17Although we have received a Fast Track designation from the FDA for TTI-101 for HCC, we may not benefit from a faster development or regulatory review or approval process, and a Fast Track designation does not increase the likelihood that our product candidates will receive marketing approvalNew
18Even if a product candidate we develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial successNew
19We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than usNew
20Compliance with governmental regulations regarding the treatment of animals used in research could increase our operating costs, which would adversely affect the commercialization of our productsNew
21If product liability lawsuits are brought against us, we may incur substantial financial or other liabilities and may be required to limit commercialization of our product candidatesNew

Risks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance

22Further, the FDA and its foreign counterparts may respond to any NDA that we may file by defining requirements that we do not anticipate. Such responses could delay clinical development of TTI-101, TTI-109 or any other current or future product candidatesNew
23Coverage and reimbursement may be limited or unavailable or pricing unfavorable in certain market segments for our product candidates, if approved, which could make it difficult for us to sell any product candidates profitablyNew
24In the United States, as well as foreign jurisdictions, no uniform policy of coverage and reimbursement for products exists among third-party payorsNew
25Recently enacted legislation, future legislation and other healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and commercialize product candidates and may affect the prices we may setNew
26Congress is considering proposed legislation intended to further reduce healthcare costs with alternatives to replace the expired ACA subsidies New
27If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our businessNew
28Our future growth may depend, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties that could materially adversely affect our businessNew
29Governments outside the United States tend to impose strict price controls, which may adversely affect our revenue, if any94% rewritten

Risks Related to Our Intellectual Property

30procedural, documentary, fee payment and other similar provisions during the patent application process. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our businessNew
31The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we, our licensor or any future collaborators or partners will be successful in protecting our product candidates by obtaining and defending patentsNew
32We do not currently own or in-license any composition of matter patent protection for the TTI-101 molecule. As such, we rely solely upon patents related to methods of use, manufacturing and pharmaceutical compositionsNew
33It is difficult and costly to protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protectionNew
34all relevant information has been identified. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our own patent portfolioNew
35Our intellectual property licensed from third parties may be subject to retained rightsNew
36Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of timeNew
37Changes in the interpretation of patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our productsNew
38We may not be able to seek or obtain patent protection throughout the world or enforce such patent protection once obtainedNew
39In order to protect our competitive position around our product candidates, we may become involved in lawsuits to enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful and which may result in our own or in-licensed patents being found invalid or unenforceableNew
40If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidatesNew
41Others may challenge inventorship or claim an ownership interest in our intellectual property which could expose us to litigation and have a significant adverse effect on our prospectsNew
42We may be subject to claims by third parties asserting that our employees or we have misappropriated our intellectual property or claiming ownership of what we regard as our own intellectual propertyNew
43If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmedNew
44collaborators. A competitor’s discovery of our trade secrets would impair our competitive position and have an adverse impact on our businessNew
45A third party may hold intellectual property, including patent rights that are important or necessary to the development of our product candidates. It may be necessary for us to use the patented or proprietary technology of one or more third parties to commercialize our current and future product candidatesNew
46If disputes over intellectual property that we have licensed or in the future have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidatesNew
47If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our trademarks of interest and our business may be adversely affectedNew
48Intellectual property rights do not necessarily address all potential threats to our businessNew

Risks Related to Our Reliance on Third Parties

49If any of our relationships with these third-party CROs or others terminate, we may not be able to enter into arrangements with alternative CROs or other third parties or to do so on commercially reasonable termsNew
50Changes in methods of product candidate manufacturing or formulation may result in additional costs or delayNew
51Because we rely on third-party manufacturing and supply vendors, including single-source vendors and vendors in foreign jurisdictions, our supply of research and development, preclinical and clinical development materials may become limited or interrupted or may not be of satisfactory quantity or qualityNew
52If we are unable to enter into new collaborations, or if these collaborations are not successful, our business could be adversely affectedNew
53The operations of our suppliers, some of which are located outside of the United States, are subject to additional risks that are beyond our control and that could harm our business, financial condition, results of operations and prospectsNew
54Our suppliers and any future collaborators may need assurances that our financial resources and stability on a stand-alone basis are sufficient to satisfy their requirements for doing or continuing to do business with usNew

Risks Related to Managing Our Business and Operations

55We may encounter difficulties in managing our growth, which could adversely affect our operationsNew
56If we lose key management personnel, or if we fail to recruit additional highly skilled personnel, our ability to develop current product candidates or identify and develop new product candidates will be impaired, could result in loss of markets or market share and could make us less competitiveNew
57Our employees, independent contractors, consultants, commercial partners, collaborators and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements90% rewritten
58We or the third parties upon whom we depend may be adversely affected by natural disasters, and our business continuity and disaster recovery plans may not adequately protect us from a serious disasterNew
59The market price of our common stock is expected to be volatileNew
60Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common stockNew
61We have, and expect to continue to, incur significant legal, accounting and other expenses that we did not incur as a private company, including costs associated with public company reporting requirementsNew
62Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our managementNew
63that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of DelawareNew
64We do not anticipate paying any cash dividends in the foreseeable futureNew
65An active trading market for our common stock may not develop and our stockholders may not be able to resell their shares of common stock for a profit, if at allNew
66Future sales of shares by existing stockholders could cause our stock price to declineNew
67If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline81% rewritten
68If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired96% rewritten
69If we fail to attract and retain management and other key personnel, we may be unable to continue to successfully develop or commercialize our product candidates or otherwise implement our business planNew
70We are expected to take advantage of reduced disclosure and governance requirements applicable to smaller reporting companies, which could result in our common stock being less attractive to investorsNew
71Changes in tax laws may materially adversely affect our business, prospects, financial condition and operating resultsNew
72Our ability to use net operating loss carryforwards and other tax attributes may be limited, including as a result of the Merger100% rewritten
73We are subject to the SEC requirements applicable to reporting shell company business combinations. As a result, we are subject to more stringent reporting requirements, offering limitations and resale restrictionsNew
74In the past, securities class action or stockholder derivative litigation often follows certain significant business transactions, such as the sale of a business division or announcement of a merger. We are involved and may continue to be involved in this type of litigation in connection with the MergerNew
75These material weaknesses could result in a misstatement of substantially all of our accounts or disclosures that would result in a material misstatement of our future annual or interim financial statements that would not be prevented or detected. These material weaknesses must be remediated by usNew
76Our disclosure controls and procedures may not prevent or detect all errors or acts of fraudNew
77Our issuance of additional capital stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholdersNew
78If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could declineNew
79We will incur significant increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiativesNew
80and resources to comply or defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operationsNew
81attempts in the past and expect such attempts will continue in the future. A security incident or other interruption could disrupt our ability (and that of third parties with whom we work) to operate our businessNew
82Unfavorable global economic conditions could adversely affect our business, financial condition or results of operationsNew
83The increasing use of social media platforms presents new risks and challengesNew

Other Tvardi Therapeutics 10-Ks

FY2024 10-K risk factors
74 risks
Tvardi Therapeutics is pursuing a reverse merger with Cara Therapeutics, involving significant ownership dilution and closing conditions.
Filed Mar 11, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.